NRx Pharmaceuticals raises $8.8M, announces HOPE Therapeutics launch and Rockefeller advisory role

NRX Pharmaceuticals, Inc.

Raised $8.8M gross from experienced biotech investors via common stock offering; no warrants or variable rate features.
HOPE Therapeutics subsidiary to launch in September 2025 with flagship location in Palm Beach, FL.
Clinics will combine ketamine, transcranial magnetic stimulation, hyperbaric oxygen for suicidal depression, PTSD, TBI.
Matthew Rockefeller joins HOPE Therapeutics Advisory Board.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.